HK2 and diffuse large B-cell lymphoma: To further assess the potential contribution of HKII to rituximab/chemotherapy resistance in a more clinically relevant setting, we analyzed gene expression profiling data from 401 patients with DLBCL treated with CHOP- (n = 181) or R-CHOP-like treatment (n = 220) as front-line therapy.